Postinflammatory hyperpigmentation - Hyperpigmentation Postinflammatory
Cyflwr croenol yw Hyperpigmentation Postinflammatory (Postinflammatory hyperpigmentation) a nodweddir gan fwy o bigment yn y croen yn dilyn llid y croen. Gall hyperpigmentation postinflammatory (postinflammatory hyperpigmentation) gael ei achosi gan amlygiad hirfaith i'r haul, llid, neu anafiadau eraill i'r croen, gan gynnwys y rhai sy'n gysylltiedig ag acne. Mae pobl â thonau croen tywyllach fel arfer yn fwy tueddol o orbigmentu gyda gormod o amlygiad i'r haul.
☆ Yng nghanlyniadau Stiftung Warentest 2022 o’r Almaen, roedd boddhad defnyddwyr â ModelDerm ond ychydig yn is nag ymgynghoriadau telefeddygaeth taledig.
References
Postinflammatory hyperpigmentation (PIH) yn broblem croen aml sy'n digwydd ar ôl llid y croen neu anaf. Mae'n tueddu i bara am amser hir ac mae'n waeth mewn pobl â thonau croen tywyllach (Fitzpatrick skin types III–VI) . Er ei fod yn aml yn gwella ar ei ben ei hun, gall hyn gymryd peth amser, felly mae angen triniaeth am amser hir yn aml. Mae cyfuno gwahanol driniaethau yn gweithio orau.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Mae Postinflammatory hyperpigmentation yn ddilyniant cyffredin o lid y croen. Mae'n tueddu i effeithio ar unigolion â chroen tywyllach yn fwy difrifol ac aml. Mae astudiaethau'n dangos bod materion fel postinflammatory hyperpigmentation ymhlith y prif resymau pam mae pobl â thonau croen tywyllach yn ceisio gofal dermatolegol. Mae triniaeth gynnar yn hanfodol ar gyfer datrys postinflammatory hyperpigmentation ac fel arfer yn dechrau gyda rheoli'r cyflwr llidiol cychwynnol. Mae'r driniaeth gyntaf fel arfer yn cynnwys defnyddio cyfryngau cyfoes sy'n ysgafnhau'r croen ynghyd ag eli haul i'w hamddiffyn. Gall yr asiantau hyn, fel hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , leihau pigmentiad gormodol yn effeithiol. Yn ogystal, mae retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy hefyd yn cael eu defnyddio fel cyfryngau debigmentu, gyda thriniaethau newydd yn dod i'r amlwg. Er bod triniaethau amserol fel arfer yn effeithiol ar gyfer gorbigmentu ar lefel wyneb, efallai y bydd angen gweithdrefnau (laser, chemical peel) ar gyfer achosion ystyfnig. Mae'n bwysig bod yn ofalus gyda'r triniaethau hyn i osgoi llid a gwaethygu postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
